Roche’s Genentech unit has said will reintroduce its Susvimo implant for eyesight-robbing disease age-related macular degeneration (AMD), which was withdrawn from sale in 2022 due to ...
The implant is refillable and about the size of a grain of rice, continuously delivering ranibizumab over a period of months. The need for frequent injections with Lucentis and other wet AMD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback